Differentiating on tolerability, raising the bar for efficacy and concentrating small molecule development on indications with minimal IRA exposure are all pieces of Novartis CEO Vasant Narasimhan’s strategy to break into the top pharmas by U.S. sales. Two data readouts this week — one for CML drug Scemblix at ASCO and one for inflammatory disease therapy remibrutinib at the EAACI Congress — may tee up two launches to advance that goal through a strategy focused on prioritizing blockbuster-bound programs. Narasimhan discusses the readouts with Editor in Chief Simone Fishburn on a Special Edition of The BioCentury Show.View full story: #biotech #biopharma #pharma #lifescience00:00 - Intro01:12 - CML Data09:34 - Endpoints, Approval Pathway13:00 – Remibrutinib24:07 – IRA, Radioligands

Intro01:12 - CML Data09:34 - Endpoints, Approval Pathway13:00 – Remibrutinib24:07 – IRA, Radioligands

Ep. 62 - Rick Bright: Navigating the Avian Flu Threat

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.Don't miss this event, every two weeks, now available as a video webcast or audio podcast.